IMPACT BIOMEDICAL INC.
IBODrugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
IMP4927
Ovarian Cancer
Senaparib
Ovary Cancer
IMP4297
Ovarian Cancer
IMP9064
Solid Tumor
IMP4297(senaparib)
Advanced Solid Tumours
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMP4927 | Phase 3 | Ovarian Cancer | - | - |
Senaparib | Phase 2 | Ovary Cancer | - | - |
IMP4297 | Phase 2 | Ovarian Cancer | - | - |
IMP9064 | Phase 2 | Solid Tumor | - | - |
IMP4297(senaparib) | Phase 2 | Advanced Solid Tumours | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in IMPACT BIOMEDICAL INC.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in IMPACT BIOMEDICAL INC.'s (IBO) pipeline across Phase 3, Phase 2. Its lead program is IMP4927 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IMPACT BIOMEDICAL INC.'s next FDA catalyst?→
IMPACT BIOMEDICAL INC.'s (IBO) next tracked catalyst is a Earnings expected November 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IBO biotech catalysts?→
Add IBO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IMPACT BIOMEDICAL INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.